A 59-year-old with T2D, CKD (UACR 220) and ASCVD on ACEi and SGLT2i asks about additional CV-renal protection. Which option has evidence for HF/CV ben...

Question

A 59-year-old with T2D, CKD (UACR 220) and ASCVD on ACEi and SGLT2i asks about additional CV-renal protection. Which option has evidence for HF/CV benefit and may reduce albuminuria?

Accepted Answer

CKD (UACR 220)

Answer

and ASCVD on ACEi and SGLT2i asks about additional CV-renal protection. Which option has evidence for HF/CV benefit and may reduce albuminuria?

Answer

DPP-4 inhibitor

Answer

GLP-1 receptor agonist with proven CV benefit

Answer

TZD

"moderate" MCQ (SBA): Endocrinology

A 59-year-old with T2D, CKD (UACR 220) and ASCVD on ACEi and SGLT2i asks about additional CV-renal protection. Which option has evidence for HF/CV benefit and may reduce albuminuria?